TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2716439
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg tenilsetam
Study: 2716439
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg co-dergocrine-mesylate
Study: 7023894
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg naltrexone administered thrice weekly
Study: 7023894
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg naltrexone administered thrice weekly
Study: 30375144
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1 (40-70 J)
Study: 27677161
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral suspension (500,000 units, QID)
Study: 19646801
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (10-month supervised program, 3 times weekly)
Study: 18298872
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of levobupivacaine and clonidine
Study: 18298872
Drug: Lumbar plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar plexus infusion of levobupivacaine and clonidine
Study: 11488732
Drug: Interstitial radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial radiofrequency therapy (IRFT)
Study: 3815009
Drug: iohexol, 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol, 350 mg I/ml (Omnipaque, Nycomed UK Ltd)
Study: 3815009
Drug: iopamidol, 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol, 370 mg I/ml (Niopam, E. Merck Ltd)
Study: 31393518
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine therapy (control group)
Study: 1681162
Drug: sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan 100 mg
Study: 2109197
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg per day)
Study: 16027128
Drug: Social Behaviour
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Behaviour and Network Therapy (SBNT)
Study: 11262514
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and nonexposure-based behavior therapy
Study: 9555821
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel and cream containing polyolprepolymer‐2
Study: 9555823
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin cream containing polyolprepolymer‐2
Study: 9555821
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel containing polyolprepolymer‐2 and three tretinoin prototype creams containing polyolprepolymer‐2
Study: 9555821
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin gel formulation containing polyolprepolymer‐2
Study: 3063051
Drug: Ointments containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointments containing nystatin and/or fusidic acid
Study: 31553661
Drug: Whole-Brain Radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-Brain Radiation Therapy (WBRT)
Study: 19001559
Drug: Desvenlafaxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (100 mg/d)
Study: 8783954
Drug: Intravenous cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocktail of pethidine and diazepam
Study: 1728807
Drug: High-potency multivitamin-mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency multivitamin-mineral supplement
Study: 6705484
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of propranolol
Study: 6705484
Drug: Intravenous injections
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injections of phentolamine
Study: 6705484
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of neostigmine
Study: 20644555
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg PI2 in a minidrink
Study: 17199056
Drug: Systematic depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic depression treatment program delivered by specialized nurses over 12 months
Study: 17199056
Drug: Systematic depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic depression treatment program
Study: 7782594
Drug: Mezlocillin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (150 mg/kg/12 h)
Study: 6265082
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction chemotherapy (high-dose cyclophosphamide, doxorubicin, and VP-16-213)
Study: 2224784
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction chemotherapy
Study: 14599261
Drug: Both nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both nicotine patch and bupropion
Study: 10381299
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg (o.a.d. or b.i.d.)
Study: 29695589
Drug: high‐dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐dose intravenous crenezumab 15 mg/kg every 4 weeks (n = 247)
Study: 22102056
Drug: β-alanine (BA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-alanine (BA, 2×800 mg tablets, 3× daily; CarnoSyn®; n=13)
Study: 22102056
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, 2×800 mg maltodextrin tablets, 3× daily; n=11)
Study: 3181146
Drug: i.v. etomidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. etomidate (0.3 mg kg‐1)
Study: 3181146
Drug: thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiopentone (4 mg kg‐1)
Study: 31172828
Drug: Leucine (LEU)
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine (LEU) supplement
Study: 31172828
Drug: Leucine-enriched BCAA
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched BCAA (LBCAA) supplement
Study: 31172828
Drug: Standard BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BCAA supplement
Study: 28727924
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy intervention, assessed at 2 weeks for pain reduction.
Study: 17587710
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin plus aspirin
Study: 9346426
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline (placebo) administration
Study: 3518312
Drug: Prednisolone 1.5
Normalized name: fluprednisolone 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1.5 mg/kg bw daily, taken in the morning once every three days for 30-45 days
Study: 3518312
Drug: Prednisolone 30-60
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30-60 mg daily
Study: 29444778
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill (SBP)
Study: 26727154
Drug: Home-use laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use laser device combined with antioxidant facial treatment for 12 weeks followed by 2-week regression period
Study: 12057615
Drug: Two dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose schedule (0 and 6 months) using Twinrix paediatric (360 EL.U HAV antigen/10 microg HBs antigen)
Study: 12057615
Drug: Three dose
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose schedule (0, 1 and 6 months) using adult formulation (720 EL.U HAV antigen/20 microg HBs antigen)
Study: 7916546
Drug: Somatostatin (SST)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SST) administered intrathecally and epidurally, mean daily dose 1,252 μg (range 250-3,000 μg), mean duration 11.3 days
Study: 179223
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with Adriamycin
Study: 27979753
Drug: HC2 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HC2 intervention arm CCCs receive implementation of a daily curricula for teachers/parents, children, snack, beverage, physical activity, and screen time policies, and technical assistance with menu modifications.
Study: 26743856
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice a day
Study: 26743856
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice a day (in patients with EGFR mutations)
Study: 16424116
Drug: Soluble fiber
Normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fiber supplement (3 g/d)
Study: 21696732
Drug: Single-dose fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose fosfomycin trometamol
Study: 23908551
Drug: Diclofenac 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 4% spray gel
Study: 21284481
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks)
Study: 18035519
Drug: Residential cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential cognitive therapy (RCT)
Study: 7673657
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg
Study: 3314645
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg phenoxybenzamine orally
Study: 10771224
Drug: ICRS implantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRS implantation (Intacs) in unilateral treatment group
Study: 27043681
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (once-daily) from admission day until discharge
Study: 27043681
Drug: No atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atorvastatin treatment until discharge, atorvastatin started after discharge
Study: 12848776
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg DEX hydro-bromide preceded at 1 h by quinidine HCl (50 mg)
Study: 12124547
Drug: Aprotinin (G-2)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (G-2)
Study: 21659848
Drug: 8% pirfenidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% pirfenidone (PFD) gel administered topically 3 times a day during 6 months
Study: 7241460
Drug: Pressure therapy
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure therapy
Study: 25030
Drug: Diluted diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted diazepam (10 mg diluted to 20-40 ml)
Study: 21752315
Drug: Deferasirox (DFX)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox (DFX) treatment at 30-40 mg/kg•d
Study: 17437788
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m² on days 1 and 8 plus 70 mg/m² cisplatin or carboplatin (AUC 5) on day 1, repeated every 21 days for 6 cycles
Study: 16342089
Drug: AZD3582 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 375 mg twice a day
Study: 16342089
Drug: AZD3582 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3582 750 mg twice a day
Study: 16342089
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg once a day
Study: 2525984
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice a day
Study: 2789926
Drug: BRL 24924
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 24924 1 mg
Study: 2789926
Drug: BRL 24924
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 24924 2 mg
Study: 4685619
Drug: Isoprenaline inhalation
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline inhalation by bronchial asthmatics
Study: 20299408
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (fentanyl ITS)
Study: 20299408
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous (IV) patient-controlled analgesia (PCA)
Study: 12696399
Drug: WHO/ORS (311
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO/ORS (311 mOsml/L)
Study: 12696399
Drug: Low-osmolarity solution
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolarity solution (245 mOsm/L)
Study: 10215673
Drug: levo-alpha-acetylmethadol (LAAM)
Normalized name: Levo-alpha-acetylmethadol
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: levo-alpha-acetylmethadol (LAAM) 60 mg/70 kg p.o.
Study: 10215673
Drug: methadone 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: methadone 60 mg/70 kg p.o.
Study: 10215673
Drug: naloxone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 1.0 mg/70 kg i.m. after LAAM
Study: 8965941
Drug: Dietary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and laxative treatment, combined with biofeedback training
Study: 1829515
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (20 micrograms) in Group A, 4 doses at 0, 1, 2, and 12 months.
Study: 1829515
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (10 micrograms) in Group B, 4 doses at 0, 1, 2, and 12 months.
Study: 6624186
Drug: Verapamil (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160 mg orally)
Study: 6624186
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg orally)
Study: 29299592
Drug: Fluorouracil, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, 5% cream (n=468)
Study: 25950503
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream (n=464)
Study: 10192638
Drug: Methanesulfonyl fluoride
Normalized name: Methanesulfonyl Fluoride
DrugBank: Methanesulfonyl Fluoride (DB13058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanesulfonyl fluoride (MSF) at doses of up to 0.18 mg/kg given three times per week for 16 weeks
Study: 7754477
Drug: Piretanide SR
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide SR 6 mg/day
Study: 2271089
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g coconut oil)
Study: 15105059
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 0.75 mg twice, 12 hours apart
Study: 27813052
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg 3 times a day, n=20)
Study: 24008977
Drug: Methotrexate (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.05 mg/kg bolus followed by 0.05 mg/kg/h for 6 h)
Study: 10364087
Drug: Lovastatin therapy
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin therapy (60 mg daily)
Study: 1992319
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg daily in the first phase, 200 mg daily in the second phase)
Study: 31521192
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy after initial treatment with TNF-alpha inhibitor and methotrexate
Study: 29071949
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) stimulation of Zusanli (ST 36) and Neiguan (PC 6) for 30 min, once daily for 5 days
Study: 25175124
Drug: Intravenous ultra-high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ultra-high dose methylcobalamin (MeCbl), 25 mg/day for 10 days followed by monthly 25 mg for 5 months
Study: 25175124
Drug: Intravenous ultra-high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ultra-high dose methylcobalamin (MeCbl)
Study: 21967833
Drug: Edaravone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (30 mg) during t-PA infusion
Study: 21967833
Drug: Non-Edaravone (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Edaravone (no edaravone during t-PA infusion)
Study: 15222407
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg)
Study: 12052282
Drug: Lipid disorder
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid disorder therapy (specific treatment for lipid disorder)
Study: 12052282
Drug: Lipid disorder
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid disorder therapy (for primary prevention of heart disease)
Study: 9671997
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser therapy
Study: 7924321
Drug: Progestogen-only contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only contraceptives (pill, DMPA, NET-EN, NORPLANT implants)
Study: 2810536
Drug: Cefamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1 gm intravenously every 6 hours for nine doses)
Study: 2810536
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 gm intravenously every 6 hours for nine doses)
Study: 28645473
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with non-DHP CCBs
Study: 22995326
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (FMT) 3g, 2 doses separated by 72 hours
Study: 19793846
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d anthocyanins as cyanidin glycosides (from elderberry) for 12 weeks
Study: 8422624
Drug: Phase II
Normalized name: Coxiella burnetii phase II Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II single agents (MGBG, DHAD, AZQ)
Study: 27416102
Drug: Risperidone ISM
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone ISM (all doses)
Study: 20202147
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 mcg/day
Study: 20202147
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 or 10 mg tablet according to age
Study: 18284403
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate (MPA) 0.1% cream twice weekly plus emollient (Advabase)
Study: 15665203
Drug: Therapeutic needle
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic needle treatment
Study: 15665203
Drug: Placebo needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo needle treatment
Study: 12856118
Drug: Isovolaemic HVHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolaemic HVHF (6 l/h of replacement fluid) with varying pre-dilution rates
Study: 10096930
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment consisting of omeprazole, clarithromycin, and tinidazole in H pylori-positive patients and clarithromycin alone in C pneumoniae-positive patients.
Study: 8902551
Drug: Ramipril at
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril at previous doses (treated group T, n = 8)
Study: 30219454
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice a day for 3 weeks (placebo group)
Study: 23227307
Drug: Standard-dose Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose Tacrolimus (SD) with EC-MPS 720mg bid
Study: 18396035
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg morphine/bolus (MO group)
Study: 18396035
Drug: Subanaesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanaesthetic ketamine plus 2/3 the standard dose of morphine
Study: 12617614
Drug: Buckwheat honey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buckwheat honey (1.5 g/kg body weight)
Study: 11067718
Drug: Pneumo 23°
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumo 23° pneumococcal vaccine
Study: 11067718
Drug: Older pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older pneumococcal vaccines
Study: 1317764
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of lithium carbonate
Study: 1317764
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of lithium carbonate
Study: 15761201
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen therapy via facemask for 8 hours
Study: 10849219
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion of 50 mU insulin/mL at 1 mL/h
Study: 9380317
Drug: 21‐mg transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg transdermal nicotine for 8 hours